Alladapt Immunotherapeutics, Inc. Email Format
Biotechnology ResearchCalifornia, United States0-1 Employees
Alladapt Immunotherapeutics, Inc. is a biopharmaceutical company focused on developing prescription therapies for unmet needs in the field of food allergy. Its lead program, ADP101, is a multi-allergen oral immunotherapy aimed at treating IgE-mediated food allergies, with recent interim data from a Phase 1/2 study and regulatory activity highlighted in industry news. Based in Menlo Park, California, the company operates in the biotechnology research space and engages in clinical-stage development aimed at addressing allergic conditions through immunotherapy. The organization appears to be in the clinical development phase with a focus on advancing therapies for food allergy, targeting patients and clinicians seeking new treatment options where current remedies fall short.